Risk factor
Very high price volatility
Profitability factor
Very weak growth
About
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats...
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. Specifically, the stock is overvalued on EV/EBITDA, reasonabl
Target Price
The average target price of STAA is 24 and suggests 34% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell